SCYX ▲ +2.2% - SCYNEXIS, Inc.
$SCYX - SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
06-OCT-2026 07:30 AM ET
Share this post
More filings for $SCYX
SCYX ▲ +4.0% - SCYNEXIS, Inc.Oct 22, 2026SCYX ▼ -1.0% - SCYNEXIS, Inc.Oct 21, 2026SCYX ▲ +5.7% - SCYNEXIS, Inc.Sep 28, 2026SCYX ▲ +14.9% - SCYNEXIS, Inc.Sep 28, 2026SCYX ▲ +0.5% - SCYNEXIS, Inc.Sep 22, 2026SCYX ▼ -0.2% - SCYNEXIS, Inc.Sep 10, 2026
View full $SCYX filing history →💬 Comments
Loading comments…
Leave a comment